Kyvernitakis I, et al. - Authors evaluated whether or not tamoxifen has an impact on the fracture risk in pre- and postmenopausal women with breast cancer. Patients involved in this trial had breast cancer, were taking tamoxifen, and were between 18 and 90 years of age. An increased risk of fracture was seen in premenopausal women with breast cancer treated with tamoxifen vs healthy controls. No risk reduction was seen in postmenopausal women on tamoxifen. A 75% higher risk of fracture was seen in patients between 18 and 50 years receiving tamoxifen vs healthy controls.